Key Highlights
- Michael Stella, CEO of Ascend Advanced Therapies, joins GeminiBio‘s Board of Directors.
- Brings 20+ years of experience in cell and gene therapy manufacturing.
- Previously held executive roles at Cognate Bioservices, guiding it to an $875M exit.
- Strengthens GeminiBio’s position in bioproduction and raw materials supply chains.
- Board includes industry leaders from Thermo Fisher, CLS, Abzena, and PTSI.
Source: Business Wire
Notable Quotes
- “GeminiBio plays a critical role in the supply chain for cell and gene therapy manufacturers. By leveraging their solutions, companies can avoid costly infrastructure investments while accelerating time to market.” — Michael Stella, CEO at Ascend Advanced Therapies
- “With Mike Stella joining our board, we gain decades of expertise in manufacturing and operations, allowing us to better align our media and buffer solutions with customer needs.” — Cory Stevenson, Executive Chairman at GeminiBio
Why This Matters
The addition of Michael Stella to GeminiBio’s Board of Directors enhances the company’s ability to serve cell and gene therapy manufacturers by improving supply chain efficiencies. With deep expertise in bioprocessing, operations, and CDMO leadership, Stella’s insights will help GeminiBio streamline raw material supply and support the rapid development of life-saving therapies. This strategic move strengthens GeminiBio’s commercial excellence and customer-focused solutions in the fast-growing biopharmaceutical sector.
